ELANCO ANIMAL HEALTH INC (ELAN) Stock Fundamental Analysis

NYSE:ELAN • US28414H1032

25.13 USD
+0.34 (+1.37%)
At close: Feb 13, 2026
25.3587 USD
+0.23 (+0.91%)
After Hours: 2/13/2026, 8:05:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall ELAN gets a fundamental rating of 4 out of 10. We evaluated ELAN against 191 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of ELAN while its profitability can be described as average. ELAN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ELAN was profitable.
  • In the past year ELAN had a positive cash flow from operations.
  • ELAN had negative earnings in 4 of the past 5 years.
  • Of the past 5 years ELAN 4 years had a positive operating cash flow.
ELAN Yearly Net Income VS EBIT VS OCF VS FCFELAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • ELAN has a Return On Assets of 0.27%. This is in the better half of the industry: ELAN outperforms 78.01% of its industry peers.
  • ELAN's Return On Equity of 0.53% is fine compared to the rest of the industry. ELAN outperforms 79.58% of its industry peers.
  • ELAN has a Return On Invested Capital of 1.38%. This is in the better half of the industry: ELAN outperforms 78.01% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ELAN is significantly below the industry average of 12.64%.
Industry RankSector Rank
ROA 0.27%
ROE 0.53%
ROIC 1.38%
ROA(3y)-2.13%
ROA(5y)-2.51%
ROE(3y)-5.1%
ROE(5y)-5.7%
ROIC(3y)1.73%
ROIC(5y)N/A
ELAN Yearly ROA, ROE, ROICELAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 -10 -15

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.78%, ELAN is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
  • ELAN's Profit Margin has improved in the last couple of years.
  • With a decent Operating Margin value of 5.25%, ELAN is doing good in the industry, outperforming 79.06% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ELAN has declined.
  • ELAN has a better Gross Margin (54.96%) than 67.02% of its industry peers.
  • In the last couple of years the Gross Margin of ELAN has remained more or less at the same level.
Industry RankSector Rank
OM 5.25%
PM (TTM) 0.78%
GM 54.96%
OM growth 3Y-3.95%
OM growth 5Y-14.04%
PM growth 3YN/A
PM growth 5Y28.06%
GM growth 3Y-0.22%
GM growth 5Y1.04%
ELAN Yearly Profit, Operating, Gross MarginsELAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ELAN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ELAN has more shares outstanding
  • The number of shares outstanding for ELAN has been increased compared to 5 years ago.
  • The debt/assets ratio for ELAN has been reduced compared to a year ago.
ELAN Yearly Shares OutstandingELAN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
ELAN Yearly Total Debt VS Total AssetsELAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.47, we must say that ELAN is in the distress zone and has some risk of bankruptcy.
  • ELAN's Altman-Z score of 1.47 is in line compared to the rest of the industry. ELAN outperforms 56.54% of its industry peers.
  • The Debt to FCF ratio of ELAN is 11.12, which is on the high side as it means it would take ELAN, 11.12 years of fcf income to pay off all of its debts.
  • ELAN has a Debt to FCF ratio of 11.12. This is in the better half of the industry: ELAN outperforms 79.06% of its industry peers.
  • A Debt/Equity ratio of 0.59 indicates that ELAN is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.59, ELAN is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 11.12
Altman-Z 1.47
ROIC/WACC0.16
WACC8.62%
ELAN Yearly LT Debt VS Equity VS FCFELAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

  • ELAN has a Current Ratio of 2.40. This indicates that ELAN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.40, ELAN is in line with its industry, outperforming 43.46% of the companies in the same industry.
  • A Quick Ratio of 1.23 indicates that ELAN should not have too much problems paying its short term obligations.
  • ELAN has a worse Quick ratio (1.23) than 71.73% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 1.23
ELAN Yearly Current Assets VS Current LiabilitesELAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.94% over the past year.
  • The Earnings Per Share has been decreasing by -3.01% on average over the past years.
  • The Revenue has been growing slightly by 3.08% in the past year.
  • The Revenue has been growing slightly by 7.65% on average over the past years.
EPS 1Y (TTM)12.94%
EPS 3Y-4.66%
EPS 5Y-3.01%
EPS Q2Q%46.15%
Revenue 1Y (TTM)3.08%
Revenue growth 3Y-2.33%
Revenue growth 5Y7.65%
Sales Q2Q%10.39%

3.2 Future

  • Based on estimates for the next years, ELAN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.39% on average per year.
  • Based on estimates for the next years, ELAN will show a small growth in Revenue. The Revenue will grow by 4.96% on average per year.
EPS Next Y5.08%
EPS Next 2Y7.19%
EPS Next 3Y9.06%
EPS Next 5Y10.39%
Revenue Next Year5.5%
Revenue Next 2Y5.65%
Revenue Next 3Y5.52%
Revenue Next 5Y4.96%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ELAN Yearly Revenue VS EstimatesELAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
ELAN Yearly EPS VS EstimatesELAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 26.18 indicates a quite expensive valuation of ELAN.
  • Compared to the rest of the industry, the Price/Earnings ratio of ELAN indicates a somewhat cheap valuation: ELAN is cheaper than 78.01% of the companies listed in the same industry.
  • ELAN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.97, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 24.04, which indicates a rather expensive current valuation of ELAN.
  • Based on the Price/Forward Earnings ratio, ELAN is valued a bit cheaper than the industry average as 74.35% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of ELAN to the average of the S&P500 Index (27.96), we can say ELAN is valued inline with the index average.
Industry RankSector Rank
PE 26.18
Fwd PE 24.04
ELAN Price Earnings VS Forward Price EarningsELAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ELAN is valued cheaply inside the industry as 81.68% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, ELAN is valued cheaply inside the industry as 81.15% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 34.49
EV/EBITDA 17.38
ELAN Per share dataELAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ELAN does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.15
PEG (5Y)N/A
EPS Next 2Y7.19%
EPS Next 3Y9.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ELAN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELANCO ANIMAL HEALTH INC

NYSE:ELAN (2/13/2026, 8:05:06 PM)

After market: 25.3587 +0.23 (+0.91%)

25.13

+0.34 (+1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners116.54%
Inst Owner Change-3.96%
Ins Owners0.99%
Ins Owner Change4.72%
Market Cap12.49B
Revenue(TTM)4.59B
Net Income(TTM)36.00M
Analysts85.45
Price Target26.99 (7.4%)
Short Float %4.71%
Short Ratio4.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.7%
Min EPS beat(2)30.48%
Max EPS beat(2)42.93%
EPS beat(4)3
Avg EPS beat(4)20.43%
Min EPS beat(4)-8.7%
Max EPS beat(4)42.93%
EPS beat(8)6
Avg EPS beat(8)14.04%
EPS beat(12)10
Avg EPS beat(12)44.02%
EPS beat(16)13
Avg EPS beat(16)38.17%
Revenue beat(2)2
Avg Revenue beat(2)2.27%
Min Revenue beat(2)2.06%
Max Revenue beat(2)2.48%
Revenue beat(4)3
Avg Revenue beat(4)0.91%
Min Revenue beat(4)-0.97%
Max Revenue beat(4)2.48%
Revenue beat(8)6
Avg Revenue beat(8)0.5%
Revenue beat(12)9
Avg Revenue beat(12)0.62%
Revenue beat(16)9
Avg Revenue beat(16)-0.02%
PT rev (1m)3.61%
PT rev (3m)20.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.45%
EPS NY rev (1m)0%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE 26.18
Fwd PE 24.04
P/S 2.72
P/FCF 34.49
P/OCF 19.85
P/B 1.85
P/tB N/A
EV/EBITDA 17.38
EPS(TTM)0.96
EY3.82%
EPS(NY)1.05
Fwd EY4.16%
FCF(TTM)0.73
FCFY2.9%
OCF(TTM)1.27
OCFY5.04%
SpS9.24
BVpS13.58
TBVpS-3.24
PEG (NY)5.15
PEG (5Y)N/A
Graham Number17.13
Profitability
Industry RankSector Rank
ROA 0.27%
ROE 0.53%
ROCE 1.99%
ROIC 1.38%
ROICexc 1.44%
ROICexgc 5.17%
OM 5.25%
PM (TTM) 0.78%
GM 54.96%
FCFM 7.88%
ROA(3y)-2.13%
ROA(5y)-2.51%
ROE(3y)-5.1%
ROE(5y)-5.7%
ROIC(3y)1.73%
ROIC(5y)N/A
ROICexc(3y)1.78%
ROICexc(5y)N/A
ROICexgc(3y)7.88%
ROICexgc(5y)N/A
ROCE(3y)2.5%
ROCE(5y)N/A
ROICexgc growth 3Y-9.66%
ROICexgc growth 5Y-10.16%
ROICexc growth 3Y2.68%
ROICexc growth 5Y-13.27%
OM growth 3Y-3.95%
OM growth 5Y-14.04%
PM growth 3YN/A
PM growth 5Y28.06%
GM growth 3Y-0.22%
GM growth 5Y1.04%
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 11.12
Debt/EBITDA 4.35
Cap/Depr 39.85%
Cap/Sales 5.82%
Interest Coverage 250
Cash Conversion 69.05%
Profit Quality 1005.56%
Current Ratio 2.4
Quick Ratio 1.23
Altman-Z 1.47
F-Score6
WACC8.62%
ROIC/WACC0.16
Cap/Depr(3y)24.5%
Cap/Depr(5y)32.23%
Cap/Sales(3y)3.76%
Cap/Sales(5y)4.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.94%
EPS 3Y-4.66%
EPS 5Y-3.01%
EPS Q2Q%46.15%
EPS Next Y5.08%
EPS Next 2Y7.19%
EPS Next 3Y9.06%
EPS Next 5Y10.39%
Revenue 1Y (TTM)3.08%
Revenue growth 3Y-2.33%
Revenue growth 5Y7.65%
Sales Q2Q%10.39%
Revenue Next Year5.5%
Revenue Next 2Y5.65%
Revenue Next 3Y5.52%
Revenue Next 5Y4.96%
EBIT growth 1Y-4.74%
EBIT growth 3Y-6.19%
EBIT growth 5Y-7.47%
EBIT Next Year19.45%
EBIT Next 3Y12.44%
EBIT Next 5Y9.88%
FCF growth 1Y656.92%
FCF growth 3Y9.94%
FCF growth 5Y70.08%
OCF growth 1Y395.28%
OCF growth 3Y3.85%
OCF growth 5Y19.28%

ELANCO ANIMAL HEALTH INC / ELAN FAQ

What is the ChartMill fundamental rating of ELANCO ANIMAL HEALTH INC (ELAN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ELAN.


Can you provide the valuation status for ELANCO ANIMAL HEALTH INC?

ChartMill assigns a valuation rating of 4 / 10 to ELANCO ANIMAL HEALTH INC (ELAN). This can be considered as Fairly Valued.


Can you provide the profitability details for ELANCO ANIMAL HEALTH INC?

ELANCO ANIMAL HEALTH INC (ELAN) has a profitability rating of 5 / 10.


Can you provide the financial health for ELAN stock?

The financial health rating of ELANCO ANIMAL HEALTH INC (ELAN) is 3 / 10.


Can you provide the expected EPS growth for ELAN stock?

The Earnings per Share (EPS) of ELANCO ANIMAL HEALTH INC (ELAN) is expected to grow by 5.08% in the next year.